BR112014005653A2 - uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada - Google Patents
uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderadaInfo
- Publication number
- BR112014005653A2 BR112014005653A2 BR112014005653A BR112014005653A BR112014005653A2 BR 112014005653 A2 BR112014005653 A2 BR 112014005653A2 BR 112014005653 A BR112014005653 A BR 112014005653A BR 112014005653 A BR112014005653 A BR 112014005653A BR 112014005653 A2 BR112014005653 A2 BR 112014005653A2
- Authority
- BR
- Brazil
- Prior art keywords
- benzimidazol
- methylpiperazin
- fluoro
- amino
- quinolin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535142P | 2011-09-15 | 2011-09-15 | |
| PCT/US2012/054046 WO2013039764A1 (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014005653A2 true BR112014005653A2 (pt) | 2017-03-28 |
Family
ID=46846036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014005653A BR112014005653A2 (pt) | 2011-09-15 | 2012-09-07 | uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140221389A1 (enExample) |
| EP (1) | EP2755655A1 (enExample) |
| JP (1) | JP2014526506A (enExample) |
| KR (1) | KR20140062485A (enExample) |
| CN (1) | CN103826634A (enExample) |
| AU (1) | AU2012308993A1 (enExample) |
| BR (1) | BR112014005653A2 (enExample) |
| CA (1) | CA2848210A1 (enExample) |
| IN (1) | IN2014DN02060A (enExample) |
| MX (1) | MX2014003182A (enExample) |
| RU (1) | RU2014114827A (enExample) |
| WO (1) | WO2013039764A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| EP3093014A1 (en) * | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
| EP4027989A4 (en) * | 2019-09-11 | 2023-09-06 | Inspirna, Inc. | METHOD FOR TREATING CANCER |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL211125B1 (pl) | 2000-09-11 | 2012-04-30 | Novartis Vaccines & Diagnostic | Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie |
| KR20050037585A (ko) | 2002-08-23 | 2005-04-22 | 카이론 코포레이션 | 벤지미다졸 퀴놀리논 및 그들의 사용 |
| CA2501932C (en) * | 2002-11-13 | 2014-03-11 | Chiron Corporation | Use of benzimidazole quinolinones for treating cancer |
| CN100377709C (zh) * | 2002-11-13 | 2008-04-02 | 希龙公司 | 受体酪氨酸激酶抑制剂的制药用途及相关检测方法 |
| NZ543709A (en) * | 2003-05-27 | 2009-04-30 | Robert Per Hagerkvist | Use of tyrosine kinase inhibitor to treat diabetes |
| EP1904480A2 (en) * | 2005-05-23 | 2008-04-02 | Novartis Pharma AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| WO2011063421A1 (en) * | 2009-11-23 | 2011-05-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
-
2012
- 2012-09-07 MX MX2014003182A patent/MX2014003182A/es not_active Application Discontinuation
- 2012-09-07 US US14/342,612 patent/US20140221389A1/en not_active Abandoned
- 2012-09-07 AU AU2012308993A patent/AU2012308993A1/en not_active Abandoned
- 2012-09-07 BR BR112014005653A patent/BR112014005653A2/pt not_active IP Right Cessation
- 2012-09-07 KR KR1020147006625A patent/KR20140062485A/ko not_active Withdrawn
- 2012-09-07 CN CN201280044613.4A patent/CN103826634A/zh active Pending
- 2012-09-07 IN IN2060DEN2014 patent/IN2014DN02060A/en unknown
- 2012-09-07 EP EP12758976.0A patent/EP2755655A1/en not_active Withdrawn
- 2012-09-07 WO PCT/US2012/054046 patent/WO2013039764A1/en not_active Ceased
- 2012-09-07 RU RU2014114827/15A patent/RU2014114827A/ru not_active Application Discontinuation
- 2012-09-07 JP JP2014530703A patent/JP2014526506A/ja active Pending
- 2012-09-07 CA CA2848210A patent/CA2848210A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2848210A1 (en) | 2013-03-21 |
| MX2014003182A (es) | 2014-09-22 |
| US20140221389A1 (en) | 2014-08-07 |
| AU2012308993A1 (en) | 2014-03-27 |
| JP2014526506A (ja) | 2014-10-06 |
| EP2755655A1 (en) | 2014-07-23 |
| WO2013039764A1 (en) | 2013-03-21 |
| CN103826634A (zh) | 2014-05-28 |
| KR20140062485A (ko) | 2014-05-23 |
| IN2014DN02060A (enExample) | 2015-05-15 |
| RU2014114827A (ru) | 2015-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013029246A2 (pt) | 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112014014783A2 (pt) | moléculas de inibidor de jnk para tratamento de várias doenças | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112013007681A2 (pt) | uso terapêutico de um agonista trl e terapia de combinação | |
| BR112015008447A2 (pt) | métodos para tratar câncer | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
| BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| BR112014014181A2 (pt) | combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer | |
| BR112016012410A2 (pt) | conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica | |
| BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
| IN2015DN03219A (enExample) | ||
| BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| BR112015030623A2 (pt) | agentes citotóxicos para o tratamento de câncer | |
| BR112014001170A2 (pt) | cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata | |
| BR112015003836A2 (pt) | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112013007343A2 (pt) | métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica | |
| ATE543492T1 (de) | Behandlung von lungenkrebs | |
| BR112012002246A2 (pt) | composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |